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Abstract
Cancer remains one of the leading causes of death. Research and resulting technolo-
gies have contributed to rising numbers of cancer survivors. Cancer nanotechnology
is a novel and burgeoning field with the promise to open the door for the develop-
ment of improved cancer therapies and detection methods. Cancer nanotechnology
has the potential to become clinical reality.
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Book Review
Cancer remains one of the leading causes of death. In 2009 562,340 fatalities were
reported in the US. Cancer risk factors include genetics, environmental exposures (che-
micals, infectious agents, radiation) as well as behaviors, and food choices. Research
and resulting technologies have contributed to rising numbers of cancer survivors. In
2009, 11.4 million cancer survivors have been reported in the US; 1.6 million of these
have survived cancer for more than 20 years (American Association for Cancer
Research). High-throughput screening methods and databases contribute to a better
understanding of the disease, earlier detection, and improved therapies.
Still, current detection methods do not reach the sensitivity required and che-
motherapies are generally not targeted to the site of disease, resulting in undesired side
effects. The goal of researchers is to develop targeted imaging modalities with higher
signal-to-noise ratios and targeted devices for localized drug-delivery for improved
efficacy and reduced adverse effects. Advances in nanotechnology, the exploitation of
matter on the nanometer size-scale, now open the door to realize the development of
such smart targeted devices. Nanomaterials have favorable properties for cancer
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any medium, provided the original work is properly cited.therapy: i) the particles can carry a high “payload” of drugs or a “cocktail” of several
drugs and or/imaging moieties, ii) nanoparticles can be engineered with targeting
ligands that direct the materials and “payload” to the site of disease, and iii) the parti-
cle itself can have therapeutic or diagnostic properties.
The textbook “Cancer Nanotechnology” edited by Stephen R. Grobmeyer and Brji M.
Moudgil (University of Florida) provides an interesting and valuable collection of can-
cer nanotechnologies. The focus lies in detailed descriptions of “how to” generate
nanoparticle formulations for imaging and therapeutic applications. Various synthetic
nanoparticle systems, their synthesis, characterization, as well as methods for in vitro
and in vivo evaluation are described. It should be noted, that besides synthetic nano-
particles such as liposomes, metallic nanoparticles, and polymeric systems, biological
scaffolds including nanobodies and viral nanoparticles have received growing attention
over the past years.
“Targeting” is key in cancer nanotechnology. One differentiates between active vs. pas-
sive targeting. Passive targeting is based on hypervascularization of tumors; nanomater-
ials of 10-400 nm in size extravasate tumor vasculature through the enhanced
permeability and retention (EPR) effect and thus accumulate in the tumor tissue. Meth-
ods to establish mouse tumor models and demonstration of EPR effects in vivo are
described in chapter 3. Active targeting can be achieved on two levels: first, cell surface
receptors that differentiate malignant cells from healthy cells can be targeted; this allows
one to direct the nanocarrier to the site of disease (discussed in chapter 13); several
ligand-receptor systems such as the folate receptor, aptamer systems, LHRH receptor, as
well as magnetic targeting strategies are highlighted (chapters 16, 17, 18, 19). Second,
targeting can be achieved on the molecular level inside the cell, here drugs are directed
to interfere with biochemical pathways within the cells to either destroy the cancer cell
or restore the cell’s “software” to a normal state (chapter 2).
Nanomaterials hold great promise as imaging contrast agents to improve signal-to-
noise ratios. Nanotechnology allows integration of different imaging methods through
the use of multimodal agents. Throughout the book, medical imaging technologies are
described including magnetic resonance imaging (MRI) and photoacoustic tomography
(PAT). The synthesis and characterization of the following systems is discussed: Gd-
chelated silica nanoparticles (used in MRI-PAT), gold cages and gold nanorods (used
in PAT), and superparamagnetic iron oxide nanoparticles (used in PAT) (chapters 5, 6,
8, 19, 20, 23). Cancer therapies currently under development include i) targeted che-
motherapy, ii) photothermal therapies (PTT), iii) hyperthermia therapy, and iv) photo-
dynamic therapies (the latter is not described in “Cancer Nanotechnology”). The
authors list a variety of materials: dielectric core-metal shell nanoparticles used for
PTT, gold cages and nanorods used for PTT and hyperthermia, as well as liposomal
doxorubicin and paclitaxel formulations that are used for improved chemotherapies
(chapters 6, 7, 14, 23, 24). Each of these chapters describe the synthesis and characteri-
zation of the materials as well as their in vitro and in vivo testing.
Some nanomaterials are functional by themselves, e.g. gold nanoparticles can be used
for PAT and PTT without further modification, other nanomaterials serve as carriers
to direct imaging or therapeutic compounds toward the sites of disease. In these cases
the carrier is loaded with imaging or therapeutic molecules and engineered with target-
ing ligands to direct the formulation to the tumor (alternatively passive targeting
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riers, polymeric nanoparticular systems (including PLGA), silica nanoparticles for ima-
ging, targeted gold immunoconjugates, drug-loaded dendrimers are introduced;
protocols are described in extensive detail in chapters 9, 10, 11, 12 15, 20.
Overall, the book “Cancer Nanotechnology” describes state-of-the-art concepts to
design and evaluate nanomaterials in vitro and in vivo using preclinical mouse models
or clinical trials (chapter 25 & 26). The field is rapidly developing; a broad collection
of materials is available. Liposomes and iron oxide nanoparticles have been FDA
approved, many other materials are in (pre)clinical testing. Nanotechnology has the
potential to revolutionize cancer detection and treatment. New technologies can lead
to new breakthroughs, however, new technologies bring new risks. Nanotoxicology is
an important topic. A database with reference protocols for the characterization of
nanomaterials is currently under construction (a combined effort by the National Can-
cer Institute, National Institute of Standards and Technologies, and the Nanotechnol-
ogy Characterization Laboratory) but not available yet. To fill this gap, the authors and
editors put together a truly comprehensive and helpful reference guide listing methods
for reporting particle size, porosity, materials composition, and surface properties
(chapter 4).
The field of cancer nanotechnology has grown out of its infancy. Besides developing
nanomaterials for potential applications, it is required to test and validate the designs
and gain understanding on biodistribution and potential side effects; this can only be
achieved using in vivo models. Therefore it is refreshing to see that an effort was made
toward listing and references in vivo methods in addition to synthetic methods. Cancer
nanotechnology is an exciting field; increasing knowledge is expected to open the door
for the development of improved therapies and detection methods. Cancer nanotech-
nology has the potential to become clinical reality.
Acknowledgements
This work was supported by the NIH (R00 EB009105).
Competing interests
The author declares that they have no competing interests.
Received: 21 September 2010 Accepted: 24 September 2010 Published: 24 September 2010
doi:10.1186/1475-925X-9-55
Cite this article as: Steinmetz: Review of “Cancer Nanotechnology: Methods and Protocols (Methods in Molecular
Biology)” by Stephen R. Grobmyer (Editor), Brij M. Moudgil (Editor). BioMedical Engineering OnLine 2010 9:55.
Steinmetz BioMedical Engineering OnLine 2010, 9:55
http://www.biomedical-engineering-online.com/content/9/1/55
Page 3 of 3